NCT02204943 - Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 6, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions

Bone Metastatic Castration-Resistant Prostate Cancer

Interventions

DEVICE

Biomarker analysis

Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples

DRUG

Administration of radium-223

Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.

Trial Locations (1)

27710

Duke University Medical Center, Durham